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Mutationnes are spliced and their majority is alternatively spliced. Alternative splicing is a
key element in eukaryotic gene expression that increases the coding capacity of the human genome and an
increasing number of examples illustrates that the selection of wrong splice sites causes human disease. A
ﬁne-tuned balance of factors regulates splice site selection. Here, we discuss well-studied examples that
show how a disturbance of this balance can cause human disease. The rapidly emerging knowledge of
splicing regulation now allows the development of treatment options.
© 2008 Elsevier B.V. All rights reserved.1. General principles of alternative splicing
1.1. Alternative pre-mRNA splicing regulates the function of the majority
of protein-coding genes
An average human protein-coding gene contains a mean of 8.8
exons with a mean size of 145 nt. The mean intron length is 3365 nt
and the 5′ and 3′ UTR are 770 and 300 nt, respectively; as a result, this
“standard” gene spans about 27 kbp. After pre-mRNA processing the
average mRNA exported into the cytosol consists of 1340 nt coding
sequence, 1070 nt untranslated regions and a poly (A) tail [1]. This
shows that more than 90% of the pre-mRNA is removed as introns, and
only about 10% of the average pre-mRNA is joined as exonic sequences
by pre-mRNA splicing. Almost all protein-coding genes contain
introns that are removed in the nucleus by RNA splicing during pre-
mRNA processing. Exon usage is often alternative, i.e. the cell decides
whether to remove a part of the pre-mRNA as an intron or include this
part in the mature mRNA as an alternative exon [2]; (Fig. 1).
Alternative pre-mRNA processing is a key regulator of gene expression
as it generates numerous transcripts from a single protein-coding
gene, which largely increases the use of genetic information. The
process is more widely used than previously thought andwas recently
estimated to affect more than 88% of human protein-coding genes [3].
An estimated 75% of alternative exons encode protein parts [4] and
their alternate use allows to generate multiple proteins from a singlell rights reserved.gene, which increases the coding potential of the genome. Mapping of
alternatively spliced regions on known protein structures suggest that
most alternative exons are in coiled or loop regions that are located on
the surface [5]. Alternative splicing generates protein isoforms with
different biological properties that differ in protein:protein interac-
tion, subcellular localization, or catalytic ability [6]. More than a
quarter of alternative exons introduce premature stop codons in their
mRNAs. This can result either in the formation of truncated proteins or
in the degradation of the mRNA in nonsense-mediated decay. Recent
array analyses indicate that although frequently found, alternative
exons with premature stop codons are present only in low abundance,
which question their role as a general shut-off mechanism for protein
production [7,8].
1.2. Changes in alternative splicing can be the cause or consequence of
human diseases
There are only a few reports of mutations in core elements of
the splicing machinery that result in human diseases. For example,
autosomal dominant forms of retinitis pigmentosa is caused by
mutation in the splicing factors PRPF31/U4-61k [9,10] and PRP8
[11]. It is possible that defects in the general splicing machinery are
generally not compatible with life, whereas changes in alternative
splicing can be tolerated by an organism, although these changes
might manifest in a disease. As alternative splicing affects
numerous genes, it is not surprising that changes in alternative
splicing are frequently associated with human diseases. It is often
not clear whether a change in alternative splicing causes a disease
or is an indicator for an underlying defect. A better mechanistical
understanding of splice site selection has helped in distinguishing
Fig. 1. Alternative splicing modes. Constitutive exons are shown as white boxes, introns
as vertical lines. Open arrows indicate the 3′ splice site, closed arrows the 5′ splice site. A
black box indicates a cassette exon, the most frequent form of alternative splicing.
Hatched boxes indicate other splicing modes. Alternative polyadenylation sites and
alternate promoters are shown as two other mechanisms to increase mRNA diversity.
They are mechanistically different from alternative splicing.
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an effect on splice site selection was published 20 years ago [12].
Ten years later, the ﬁrst review about the impact of exonic
mutations on splice site selection postulated that silent mutations
can interfere with exon usage and explained how these mutations
that do not change the predicted encoded protein can cause a
human disease [13]. Since then, a better understanding of
alternative splice site selection contributed to a better under-
standing of human diseases and vice versa. The number of diseases
reported to be associated with changes in alterative splicing
increased dramatically and has been frequently reviewed [14–17],
including in form of a book [18,19]. To facilitate the access to this
fast growing area for colleagues in other ﬁelds, we brieﬂy
summarize disease-relevant aspects of splice site selection, discuss
well-established examples of alternative splicing changes that lead
to human disease and point out links between the diseases and
aberrant splice site selection.Fig. 2. Elements involved in alternative splicing of pre-mRNA. Exons are indicated as boxes,
green or red boxes in exons. The 5′ splice-site (CAGguaagu) and 3′ splice-site (y)10ncagG, as
letters refer to nucleotides that remain in the mature mRNA. Two major groups of proteins,
the protein:RNA interaction is indicated by shading. The protein complex assembling around
SR-proteins can interact with U1 snRNA, which helps in the recognition of the 5′ splice site, a
site. The formation of the multi-protein:RNA complex allows discrimination between prope
mRNA sequences. Factors at the 3′ splice-site include U2AF, which recognizes pyrimidine ric
adenosine of the branch point.1.3. Alternative exons are regulated by combinatorial control through
transient formation of recognition complexes
Since splice sites follow only loose consensus sequences, the key
questions in alternative splicing regulation are: How are splice sites
recognized in the vast genomic sequence background, and how are
they differentially regulated? The mechanism of alternative splice site
recognition has been extensively reviewed [16,20–23]. Exon recogni-
tion is regulated by the interaction of proteins and ribonuclear
proteins (trans-factors), with sequence elements on the pre-mRNA
(cis-factors), which is summarized below.
1.3.1. Five small nuclear RNAs form the core of the spliceosome
During processing, the pre-mRNA has extensive, speciﬁc interac-
tion via base pairing with ﬁve small nuclear RNAs (U1, U2, U4, U5, and
U6). Early in spliceosome assembly, U1 forms a base-pairing
interaction with the 5′-splice site and U2 similarly base-pairs with
the branch-point. Then a tri-snRNP complex containing U4, U5 and U6
associates with the forming spliceosome and U4 is removed from the
complex. This allows U6 to replace U1 at the 5′ splice site and leads to
a U6–U2 interaction that brings the 5′-splice site and the branch point
close together, allowing for a transesteriﬁcation step. By forming non-
canonical interactions, U5 brings the two exons into close proximity
and allows for the second step of splicing, when the two exons are
joint. This shows that small RNAs play a crucial role in splicing and
there is increasing evidence that some of the RNAs also play a role in
catalysis of the splicing reaction [24,25].
1.3.2. Proteins assembling on the pre-mRNA allow exon recognition by
interaction with the core spliceosome
Since the information in splice sites is not sufﬁcient for regulation,
ribonuclear–protein complexes (RNPs) forming on the pre-mRNA help
in the recognition of exons (Fig. 2). The majority of splicing regulatory
proteins in these complexes belong to two major classes: hnRNPs and
SR-proteins. HnRNPs are operationally deﬁned as proteins binding to
RNA. SR-proteins are characterized by serine and arginine-rich protein
domain. These proteins contain RNA-binding and protein interaction
domains [26]. They bind with low speciﬁcity to accessible, mostly
single-stranded parts of the pre-mRNA. To overcome the low RNA-
binding speciﬁcity, splicing regulatory proteins use their protein-
interaction domains to bind to each other. Another frequent strategy to
overcome the low afﬁnity between splicing factors and theirintrons as thin lines. Splicing regulator elements (enhancers or silencers) are shown as
well as the branch point (ynyyray), are indicated (y=c or u, n=a, g, c or u). Upper-case
hnRNPs (green) and SR or SR related proteins (red), bind to splicing regulator elements;
the exon stabilizes binding of spliceosomal components, indicated in blue. For example,
s it allows hybridization (thick black line) of the U1 snRNA (black line) with the 5′ splice-
r splice-sites (bold letters) and cryptic splice-sites (small gt ag) that are frequent in pre-
h regions of the 3′ splice-sites, and help stabilize the interaction of U2 snRNP with the
16 J. Tazi et al. / Biochimica et Biophysica Acta 1792 (2009) 14–26recognition sequence is a repetitive arrangement of regulatory
sequences. For example, exon 4 of the doublesex pre-mRNA contains
six repeats, each 13 nt long, that bind to the SR-proteins tra, tra2 and
9G8 [27]. Once these protein complexes have been formed around an
exon, they aid ribonuclear protein components of the core spliceosome
in establishing an RNA:RNA interaction at the 5′ splice site and at the
branchpoint. A well-studied interaction occurs between SR-proteins
and the U1 snRNP, which is part of the spliceosome. The RNA
component of the U1 snRNP interacts with the 5′ splice site, which
deﬁnes one border of an exon. Since SR-proteins that bind to an exon
stabilize the interaction with U1 snRNP and the 5′ splice site, they
generally promote inclusion of exons to which they bind. The high
ﬁdelity of exon recognition is thus achieved by the combination of
multiple weak protein:protein, protein:RNA and RNA:RNA interac-
tions, which are schematically shown in Fig. 2. Different pre-mRNAs
seem to associate with a unique arrangement of proteins, which
constitutes the ‘splicing- or mRNP code’ [28]. By interacting with the
spliceosome, the protein complexes forming on the pre-mRNA, i.e. the
splicing code, determine which RNA parts will be removed as introns
andwhich parts will be included in themature mRNA. The low afﬁnity
of each interaction is an intrinsic property of pre-mRNAprocessing and
allows the transient formation of a speciﬁc protein:RNA complex from
several intrinsically weak interactions. This has several advantages: (i)
it allows a high sequenceﬂexibility of exonic regulatory sequences that
puts no constrains on coding requirements, (ii) the protein interaction
can be inﬂuenced by small changes in the concentration of regulatory
proteins which allows the alternative usage of exons depending on a
tissue and/or developmental-speciﬁc concentration of regulatory
factors, (iii) phosphorylation of regulatory factors that alter protein:
protein-interactions can inﬂuence splice site selection, (iv) the
regulatory proteins can be exchanged with other proteins after the
splicing reaction, allowing a dynamic processing of the RNA.
Alternative splice site selection is connected to other processing
steps, such as transcription, 5′ end capping, 3′end polyadenylation and
nuclear export. Splicing regulatory proteins often function in multiple
processing events while they remain bound to ‘their’ pre-mRNA [29].
1.3.3. The secondary structure of pre-mRNA inﬂuences splice
site selection
Secondary structures of the pre-mRNA can inﬂuence splice site
selection (reviewed in [30]). For example, the stability of a predicted
stem–loop structure at the 5′ splice site of tau exon 10 regulates usage
of this exon and the alternative exon of the ﬁbronectin gene is
inﬂuenced by secondary RNA structure [31]. Bioinformatic analysis
indicate that the splicing regulatory sequences are preferentially in a
single-stranded conformation, which allows these sequences to
interact with RNA binding proteins that mostly have a preference
for single strand RNA [32].
1.3.4. Small nucleolar RNAs regulate splice site selection
Tiling array data and detailed expression analysis of parts of the
human genome in the ENCODE project showed that the expression
data and gene structures collected in current databases are largely
incomplete [33]. Numerous noncoding regions are transcribed into
polyadenylated, stable RNAs, which are named TUF (transcript of
unknown function). Within most previously well-characterized
protein coding genes, there are large numbers of transcribed
fragments (transfrags) that could represent new exons or short
RNAs of unknown sequence. The most recent study of human gene
expression using tiling arrays demonstrates that about 57% of the
transfrags are not annotated in Genbank or EnsEMBL databases [34].
Recently, it was discovered that a snoRNA, HBII-52, regulates
alternative splicing by binding to an alternative exon of the serotonin
receptor. This snoRNA is not expressed in peoplewith the Prader–Willi
syndrome and it is likely that the lack of HBII-52 snoRNA expression
contributes to the disease [35]. In support of this theory, a child with a174,584 bp long microdeletion was reported. The deletion encom-
passes only snoRNAs: HBII-438A, all snoRNAs of the HBII-85 cluster
and 23 of the 47 HBII-52 snoRNAs. Since this child showsmost clinical
features of Prader–Willi syndrome, it is now very clear that the loss of
snoRNAs cause the disease [36], which is in agreement with genetic
studies and reﬂected by two recent mouse models [37–39]. A possible
link between snoRNPs and splice site selection was mechanistically
hard to understand, as snoRNPs reside in the nucleolus and splicing
takes place in the nucleoplasma. Recently, it was shown that nuclear
export and import factors are directly involved in U8 C/D box snoRNA
biogenesis, suggesting that C/D box snoRNPs are transported through
the nucleoplasmawhile being assembled [40]. Furthermore, the 15.5K
protein that was originally identiﬁed as part of the C/D box snoRNP
complex where it binds to a conserved kink turn, binds also to a
similar structure in the U4 snRNA where it interacts with the splicing
factor hPrp31 [41]. These ﬁndings raise the possibility that 15.5K
protein bound to snoRNPs interferes with the U4/U6 rearrangement
during splicing by interacting with hPrp31. It is therefore possible that
other small RNAs are also involved in splice site selection.
1.3.5. Exon-recognition complexes are targeted by cellular signal
transduction pathways
Cells frequently regulate alternative splicing events, often in
response to external stimuli (reviewed in [42–44]). In most cases
studied, rapid changes observed in splice site selection are inﬂuenced
by phosphorylation events that are regulated by known signal
transduction pathways. Reversible phosphorylation is a key regulatory
step in the formation of protein complexes on pre-mRNA (reviewed in
[45]). SR-proteins are phosphorylated by several kinases, including the
Clk/Sty kinase family (cdc2 like kinases, Clk1-4), the SRPK family
(SRPK1,2), mammalian PRP4, topoisomerase I, CDC2 kinase 2 [46], and
GSK3 [47]. A change in phosphorylation of the RS-domain inﬂuences
its ability to interact with other proteins. For example, phosphoryla-
tion of SRp38 decreases its binding to U170K snRNP, but increases its
binding to tra2-alpha [48]. Phosphorylation of the SR-protein SF2/ASF
increased its binding to U1 70K snRNP [49] and decreased its binding
to the RNA export factor TAP/NXF1 [50]. Finally, the ability of the RS-
domain to bind to RNA depends on its phosphorylation [49,51].
The phosphorylation is reversed by phosphatases; only about 25
serine/threonine protein phosphatases are known [52]. This is in
contrast to the estimated 474–518 protein kinases representing 1.7% of
human proteins [53]. The low number of protein phosphatases is the
result of a combinatorial control. The protein phosphatase represents
only the catalytically active subunit that forms numerous regulatory
complexes with other proteins. Splicing regulatory proteins are
dephosphorylated by protein phosphatase 1 (PP1), PP2A and protein
phosphatase 2Cgamma [54,55]. Complete blocking of phosphatases
inhibits splicing as dephosphorylation is necessary for the transester-
iﬁcation step [54,56]. However, modulation of phosphatase activity in
vitro [57] and in vivo [58,59] inﬂuences alternative exon usage,
demonstrating that adjusting phosphatase activity can be used by
cells to control alternative splicing.
1.4. Alternative exons are generated during evolution and their usage can
be changed by point mutations located outside the splice sites
Alternative exons can be generated by three mechanisms
(reviewed by [60]): (i) exon shufﬂing, where an existing exon is
duplicated within the same gene and is then alternatively spliced, (ii)
exonisation of mobile genetic elements, such as Alu elements [61] and
(iii) a transformation of formally constitutive exons into alternative
ones [62]. Since the approximately one million human Alu elements
are primate-speciﬁc elements that account for 10% of the human
genome [63], their exonisation provides a large reservoir to generate
new alternative exons. Numerous studies showed that synonymous
mutations in coding regions can inﬂuence splice site selection. There
Fig. 3. Disease causing mutations. Exons and introns are indicated as in Fig. 2. Arrows indicate repetitive elements. (A) Mutation in silencer or enhancer sequences change the
interaction between regulatory proteins and pre-mRNA, leading to changes in exon recognition. (B) Mutations in splice sites change the interaction with core spliceosomal proteins.
(C) Due to formation of secondary structures, intronic sequences can be brought close to splice sites, accounting for the effect of some intronic mutations. (D) Secondary pre-mRNA
structures contribute to exon recognition and their mutations can cause aberrant splicing. (E) Expanded repeat elements can sequester splicing regulatory proteins, changing splice
site selection in other messages. (F) Some snoRNAs regulate splice site selection and their loss can cause disease.
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nucleotide polymorphism can alter exon usage [64]. It is thus likely
that alternative exon usage is an evolutionary ‘substrate’ that is
subject to a large number of mutations. Due to the complexity of the
splicing regulation, the effects of mutations are difﬁcult to predict, but
become obvious when they lead to human diseases.
Each of the regulatory principles listed here can be altered to cause
a human disease, which is schematically summarized in Fig. 3.
2. Examples of diseases caused by alternative splicing
The sequences of exons mutated in the disease are listed in Table 1,
further access to internet information is given in Table 2.
2.1. Diseases caused by point mutations in regulatory sequences
2.1.1. Spinal muscular atrophy as an example of a recessive disease
caused by a point mutation in an exonic regulatory element
Spinal muscular atrophy (SMA) describes several different diseases
that are characterized by degeneration of alpha motoneurons in the
brainstem and spinal cord. Autosomal recessive SMA associated with
chromosome 5 is molecularly the best understood. It is characterized
by progressive paralysis caused by the loss of alpha-motor neurons in
the spinal cord. The incidence is 1:6000 to 1:10,000 for live births and
the carrier frequency is 1 in 40 [65]. SMA is the second most common
autosomal recessive disorder. Since children suffering from cystic
ﬁbrosis now largely survive childhood, it is the most frequent genetic
cause of infantile death. SMA is caused by the loss of the SMN1 gene
that encodes the SMN protein, which regulates snRNP assembly. It is
not clear how the loss of SMN protein causes the disease and leads to a
speciﬁc death of motoneurons. Mouse studies revealed that the loss of
SMN protein causes cell-type speciﬁc changes in snRNAs and a
generally reduced snRNP assembly capacity. Numerous pre-mRNA
splicing events are deregulated in all tissues analyzed. Some of the
changes observed reﬂect a shift in known alternative splicing patterns.
However, the majority of the deregulated splicing events are aberrant
mRNAs, which are normally not produced. These ﬁndings suggest that
(i) the selective death of motoneurons could be caused by the
cumulative effect of aberrantly splicingmRNAs and (ii) that changes in
cells surrounding the motoneurons cause their death [66]. Genetic
studies identiﬁed six families with eight female members that were
asymptomatic for SMA, although they inherited the same SMN1 and
SMN2 alleles as their affected siblings [67]. Plastin 3, an actin binding
protein was identiﬁed as a modiﬁer. Overexpression of plastin 3 in
SMN knock-out mice partially rescued the short neuronal axon length
causes by the absence of SMA protein. These ﬁndings argue that that
the death of motoneurons could be caused by a mechanism different
from a change in splicing. Although it is not understood how the lossof SMA protein causes the disease, it is clear that restoration of SMA
protein production would be a therapeutic approach.
Humans possess a gene, SMN2, that is almost identical to SMN1.
SMN2 was generated through a recent duplication. Although both
genes are almost identical in sequence, due to a translationally silent
C→Tchange at position6 in exon7, they have different splicingpatterns
and exon 7 is predominantly excluded in SMN2 (reviewed in [68]). This
exon-skipping event generates a truncated, less stable and probably
non-functional protein. Therefore, SMN2 cannot compensate the loss of
SMN1. At least one copy of SMN2 is retained in humans with SMA, as
lack of both SMN2 and SMN1 is embryonically lethal. Mice have only
one SMN gene where exon 7 is constitutively spliced. A homozygous
knock out of this gene is lethal. To study the splicing regulation of the
human gene in mice, transgenic animals that contain the human gene
were developed [69]. Although, in SMA patients the SMN protein is
almost completely absent from all cells, for unknown reasons, alpha
motoneurons are most severely affected and die, which causes the
muscular atrophy. The disease can manifest in four phenotypes (type I
to IV) that differ in onset and severity. The phenotypes correlate
roughly with the number of SMN2 copies in the genome, most likely
because more SMN2 copies produce more SMN protein [70]. Since
stimulation of SMN2 exon 7 usage would increase SMN protein levels
and potentially cure the disease, work has concentrated on under-
standing the regulation of exon 7. Typical for the combinatorial control
of exon regulation,multiple factors determine the regulation, including
a suboptimal polypyrimidine tract [71], a central tra2-beta1-dependent
enhancer [72] and the sequence around the C→T change at position 6.
Recent large scale mutagenesis studies indicate that a composite
regulatory exonic element termed EXINCT (extended inhibitory
context) is responsible for the regulation of exon 7 inclusion [73,74].
The exon skipping event is caused by the C→Tchange at position 6 and
currently two models are proposed for its mechanism. In one model,
the base exchange destroys the exonic enhancer that normally binds to
SF2/ASF [75,76] and in the other model, the mutation creates an
hnRNPA1 binding site that acts as a silencer [77,78]. Both models can
explain the predominant skipping of exon 7. Inclusion of exon 7
depends on a central tra2-beta1 enhancer sequence [72]. Tra2-beta1 is
an SR-related protein. Its activity is regulated by dephosphorylation
mediated by protein phosphatase 1 and, not surprisingly, exon 7 usage
depends on cellular PP1 activity [79].
SMN illustrates several common features of diseases caused by
missplicing. Evolutionary changes in the genome, here the recent
dublication of genes that facilitate their recombination, can manifest
in splicing changes. Alternative exons are regulated by numerous
factors and sequence elements and a single mutation can disturb the
balance necessary for normal exon recognition. Finally, splicing factors
are regulated by reversible phosphorylation controlled by cellular
signaling pathways.
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ratio of protein isoforms generated by alternative splicing
Tauopathies describe several diseases of the central nervous
system that show intracellular accumulations of abnormal ﬁlaments
that contain the microtubule associated protein tau. The tau protein is
encoded by a single gene (MAPT, (microtubule associated protein tau)
located on chromosome 17. The gene undergoes extensive alternative
splicing and eight of the sixteen exons are alternatively spliced. In
humans, these splicing events are spatially and temporally regulated.
For example, exons 2, 3 and 10 are adult speciﬁc and show differences
in splicing in various brain regions. The tau protein binds to
microtubules via microtubule repeat regions. One of these micro-
tubule binding regions is encoded by the alternatively used exon 10.
Exon 10 inclusion creates a proteinwith fourmicrotubule repeats (4R),
whereas exon 10 skipping creates an isoform with three repeats (3R).
This splicing event is species-speciﬁc in the adult. In humans, exon 10
is alternatively spliced in the adult, whereas in mice the exon is
constitutively used. In both species, the exon usage is regulated during
development.
Genetic studies identiﬁed rare dominant mutations in the tau gene
that caused frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17), which are collected on theworld wideweb
(http://www.molgen.ua.ac.be/ADMutations/) where currently 42
mutations are listed. The majority of the mutations affect the splicing
regulation of exon 10 that encodes part of one microtubule binding
site. The mutations in tau exon 10 helped dissect its regulatory
elements. The exon shows an alternating arrangement of four
enhancer and three silencer regions. A mutation that falls into a
silencer or enhancer regions either promotes or decreases exon usage,
respectively (reviewed in [80]). Mutations in exon 10 alter its normal
fraction of inclusion and changes of pre-mRNA encoding 3R and 4R
repeat tau isoforms were found associated with FTDP-17 (recently
reviewed by [81,82]). These data clearly suggested that the splicing
mutations cause the neuropathology by changing the ratio between
the 3R and 4R isoforms. One mechanistically well understood
mutation is N279K [83]. This mutation is caused by changing a
TAAGAAG into GAAGAAG. The GAAGAAG sequence forms the core of a
tra2-beta1 binding site. Similar to the situation in exon 7 of SMN2, this
mutated version contains two partially overlapping versions of the
GAAG binding site. Biochemical studies showed that the mutation
increases afﬁnity to tra2-beta1 in vitro [84] and cotransfections
experiments showed that tra2-beta1 promoted exon 10 inclusion inTable 2
Information about diseases on the web";Information about diseases on the web
General information about
alternative splicing
http://www.eurasnet.info/
Familial dysautonomia http://www.familialdysautonomia.org/
Frontotemporal lobar
dementias/-amyotrophic
lateral sclerosis
http://www.alsa.org/
Hutchinson–Gilford
progeria syndrome
http://www.progeriaresearch.org/
Medium-chain acyl-CoA
dehydrogenase (MCAD)
deﬁciency
http://www.fodsupport.org/mcad_fam.htm
Myotonic dystrophy http://www.myotonic.com
http://www.mda.org
Prader–Willi syndrome http://www.pwsausa.org/
http://www.fpwr.org/
Spinal muscular atrophy http://www.fsma.org/
http://www.mda.org
Tauopathies http://www.molgen.ua.ac.be/ADMutations/
Substances that inﬂuence
alternative splicing
http://www.stamms-lab.net/cpds.htm
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asparagine to lysine exchange in the mutation does not alter the
binding between tau and tubulin, the tau aggregation or microtubule
assembly [86]. These data suggested that mainly the change in the
ratio of expressed isoforms is responsible for the disease. Testing this
hypothesis in mouse models was difﬁcult, as the mouse tau gene
constitutively expresses the 4R isoform in the adult. Therefore, a
minigene of human tau, containing the promoter and all exons ﬂanked
by shortened intronic regions was expressed in mice. These constructs
show alternative splicing resembling the human situation and express
human tau protein containing either 3 or 4 microtubule binding
domains. When the mutation that promotes exon 10 inclusion
(N279K) was introduced into exon 10 of this construct, pre-mRNA
splicing was shifted as expected towards exon 10 inclusion. Interest-
ingly, the mice showed similar pathophysiology as humans with the
same mutation and also showed behavioral changes [87]. These data
suggest that a change in the ratio between 3R and 4R tau isoforms is
an important underlying cause for FTDP-17.
Abnormal intracellular tau aggregations are also found in other
tauopathies, such as Alzheimer's disease [88]. Several studies were
performed to investigate whether the 4R to 3R ratio of tau pre-mRNA
is changed in Alzheimer's disease. The studies gave conﬂicting results,
whichmost likely reﬂects that only post-mortem human tissue can be
analyzed. Two studies showed no statistical regional differences in the
4R/3R ratio [89,90], one study showed regional differences but no
clear link to Alzheimer pathology [91] and a forth study showed a
statistical signiﬁcant increase of the 4R to 3R ratio in temporal cortex.
This later study also investigated possible changes in other splicing
factors regulating exon 10 and found changes in clk2 and tra2-beta1
splicing, suggesting that multiple changes in alternative splice site
selection are either causing or contributing to Alzheimer's disease
[92]. This example shows that a change in the ratio of protein isoforms
generated by alternative splicing can cause human diseases. It further
illustrates how analysis of genetic mutants helps to understand
splicing regulation, which is often complicated due to species-speciﬁc
splicing differences. Despite these problems, animal models can be
generated that reﬂect the human pathology.
2.1.3. Hutchinson–Gilford progeria syndrome as an example for a disease
caused by an intronic mutation that activates a cryptic splice site
Hutchinson–Gilford progeria syndrome (HGPS) is a rare genetic
disorder phenotypically characterized by many features of premature
aging. It is clinically characterized by postnatal growth retardation,
midface hypoplasia, micrognathia, premature atherosclerosis, absence
of subcutaneous fat, alopecia and generalized osteodysplasia. At birth,
the appearance of patients is generally normal, but by one year of age
patients show severe growth retardation, balding and scleroderma-
tous skin changes. Patients live a median of 13.4 years and die of heart
attacks or congestive heart failure. Mutations causing HGPS have been
identiﬁed in the nuclear lamin A/C (LMNA) gene. Lamin proteins are
distributed throughout the nucleoplasm and are involved in numer-
ous functions, including DNA replication, transcription, chromatin
organization, nuclear positioning and shape, as well as the assembly/
disassembly of the nucleus during cell division. Out of 14 mutations
affecting lamin A/C, three have been reported to speciﬁcally alter
lamin A splicing. The changes in splicing lead to the production of
truncated protein products (p.G608G, p.T623S and IVS11+1GNA). Most
of the typical Hutchinson–Gilford progeria cases are due to a
recurrent, de novo point mutation in LMNA exon 11: c.1824CNT [93].
This mutation occurs in a probable exon splicing enhancer. As a result,
a cryptic splice site is activated in transcripts generated from the
mutated allele, which is located 5 nucleotides upstream of the
mutation. The use of the cryptic splice site leads to the production of a
truncated Lamin A protein lacking the last 150 base pairs of exon 11.
The truncated protein is called “progerin” and acts in a dominant
fashion to generate the HGPS phenotype.This example shows how a mutation can cause activation of a
nearby otherwise ‘hidden’, cryptic splice site.
2.1.4. LDL receptor splicing variants caused by a single nucleotide
polymorphism are a sex-speciﬁc factor for hypercholesterolemia
Hypercholesterolemia is a major risk factor for arteriosclerosis.
Low-density lipoproteins are removed from the bloodstream by the
LDL receptor (LDLR). Mutations in the LDLR are a primary cause for
hypercholesterolemia. Recently, a single nucleotide polymorphism
was identiﬁed in exon 12 of the LDLR that promotes skipping of this
exon. The SNP was found to promote exon 12 skipping in the liver of
pre-menopausal women. However, the SNP had no effect on men and
post-menopausal women. The SNP and the splicing pattern are
associated with a higher level of cholesterol in pre-menopausal
women, but not in men. Exon 12 skipping generates a truncated form
of the receptor that lacks the transmembrane domain necessary for
membrane binding and internalization. It is possible that the protein
generated by exon 12 skipping prevents, in a dominant negative form,
the uptake of LDL. This model explains the interesting ﬁnding that
exon 12 skipping caused by this SNP is associated with cholesterol
levels. The reason for the sex-dependency of the SNP is unclear, but is
possible that high estrogen levels inﬂuence transcription level of the
gene or its alternative splicing [94]. Apo lipoprotein E (ApoE) is a
ligand for the LDLR receptor and the apoE allele status is a major risk
factor for Alzheimer's disease. It was therefore investigated whether
the SNP in exon 12 of the LDLR associates with Alzheimer's disease. It
was found that the SNP associates with an increased chance to
develop Alzheimer's disease in males, but not females [95].
This example nicely illustrates that a SNP can inﬂuence alternative
splicing, which in turn predisposes to a disease. Reﬂecting the
combinatorial control of alternative exon regulation, the result of a
mutation depends on other factors, in this case the sex and age.
2.1.5. Familial dysautonomia as an example for a disease caused by a
mutation in the 5′ splice site
About 10% of roughly 80,000 mutations reported in the human
gene mutation database affect splice sites [96]. Well-studied diseases
caused by changes in splice site selection include thalassemias [97]
and Familial dysautonomia (FD). FD, (also Riley–Day syndrome,
hereditary sensory and autonomic neuropathy type III) is a recessive
disease that is caused by loss of function of the i-kappa-B kinase
complex associated protein (IKBKAP). In the Ashkenazi Jewish
population, the incidence is 1/3600 in live birth (carrier frequency
1:30) [98]. Affected children show abnormal development of the
nervous system that is associated with demyelination in various
regions. This leads to a large clinical spectrum that includes vomiting
crises, unsteady gait, and decreased perception of pain. In more than
99.5% of FD patients the 5′ splice site of exon 20 is mutated T→C in
position 6 of intron 20. This point mutation interrupts base pairing
with U1snRNA. U1 snRNA interacts both with the last three
nucleotides of the exon and the ﬁrst six nucleotides of the down-
stream intron. The majority of 5′ splice sites show complementarity to
seven base pairs of U1 snRNA. This means there are usually three
mismatches between the 5′ splice site and U1 snRNA. Bioinformatic
analyses indicate that these mismatches are not randomly distributed.
They either weaken the exonic portion of the 5′ splice site, which is
then compensated by strong binding to the intronic portion, or a weak
intronic portion is compensated by a strong exonic portion. In exon 20
of the IKBKAP gene, the exonic part of the splice site is weak, due to an
A at position −1. The T→Cmutationweakens the intronic part of the 5′
splice site, which causes exon skipping [99]. Exon 20 usage is
susceptible to a weak 5′ splice site, as the exon has a weak 3′ splice
site that has an A at the −3 position, and contains several exonic
silencer elements [100]. Array analysis indicates that IKBKAP
promotes expression of genes involved in oligodendrocyte andmyelin
20 J. Tazi et al. / Biochimica et Biophysica Acta 1792 (2009) 14–26formation, which could explain the demyelination phenotype caused
by the loss of IKBKAP [101].
The example of FD illustrates the complexity of mutations in splice
sites that have to be carefully analyzed within the context of other
regulatory elements. It further shows that a missplicing event of a key
regulatory gene can have profound impact by affecting other genes,
and ﬁnally indicates that splicing is inﬂuenced by small substances.
2.1.6. Medium-chain acyl-CoA dehydrogenase (MCAD) deﬁciency
illustrates how multiple mutations affect exon usage leading
to a human disease
Medium-chain acyl-CoA dehydrogenase (MCAD) is a mitochon-
drial enzyme that participates in the degradation of medium chain
length fatty acids. Deﬁciencies of this enzyme are the most frequently
diagnosed defect of mitochondrial beta-oxidation. The patients show
metabolic crisis, characterized by hypoglycemia, lethargy and sei-
zures, when ﬁrst exposed to viral infections or challenged by fasting.
About 20% of the infants die. MCAD deﬁciency results in accumulation
of medium-chain acylcarnitines in the urine, which can be analyzed
by mass-spectrometry. A large newborn screen showed an incidence
from 1:15,000 in the US population. The major reason for the
deﬁciency is a K304E missense mutation leading to a less active
protein [102]. The newborn screening project identiﬁed a 362C→T
missense mutation in exon 5 of the MCAD gene that causes exon
skipping and subsequent degradation of the mRNA by nonsense-
mediated decay [103]. This mutation disrupts a splicing enhancer that
is highly similar to the SF2/ASF enhancer in the SMN2 exon 7.
Cotransfection experiments demonstrate that an increase of the SF2/
ASF concentration promotes inclusion of themutated exon, suggesting
that the mutation weakens an SF2/ASF-dependent enhancer. Inter-
estingly, a synonymous mutation 351A→C was identiﬁed 11 nucleo-
tides upstream in the same exon. This mutation affects an hnRNP A1
dependent silencer. Since the exon is constitutively used in the
absence of the 362C→T SF2/ASF enhancer mutation, it has no effect on
splicing. However, in the presence of the 362C→T enhancer mutation,
it promotes exon inclusion, which antagonized the exon-skipping
effect of the 362C→T SF2/ASF enhancer mutation.
This example illustrates the ﬁne-tuned balance of positive and
negative acting factors that exists in splicing regulation. It also shows
that seemingly irrelevant mutations can have an effect on splicing
when they are combinedwith othermutations. Finally, the similarities
between the regulation of MCAD exon 5 and SMN2 exon 7 suggest that
there are degenerate ‘building blocks’ or ‘regulatory modules’ in the
splicing code.
2.1.7. Frontotemporal lobar dementias are caused by the loss of the
splicing factor TDP43
TDP43 (TAR DNA binding protein 43 kDa) was originally identiﬁed
as a transcriptional repressor that associates with the transcriptional
activator DNA region (TAR) in HIV [104] and was later also found
associated with the spermatid-speciﬁc gene SP-10 promoter [105],
reviewed in [106]. TDP43 is a member of the heterogeneous nuclear
ribonucleoproteins (hnRNP) family of proteins. The protein was later
identiﬁed as a factor that binds to 12 UG repeats that cause aberrant
skipping of exon 9 of the CFTR gene, leading to cystic ﬁbrosis [107]. It
contains two RNA binding domains. The ﬁrst RNA binding domain is
necessary and sufﬁcient for binding to RNA that contains at least four
UG repeats. In addition, TDP43 shows binding to single stranded TG
DNA repeats in vitro [108]. TDP43 is a nuclear protein and it was
therefore completely surprising when it was detected in ubiquitin-
positive, tau and alpha synuclein-negative cytosolic inclusions that are
the characteristic feature of frontotemporal lobar degeneration (FTLD)
and amyotrophic lateral sclerosis (ALS, Lou Gehring's disease) [109].
During the disease, TDP43 is cleaved by caspase-3 and the cleavage
fragments accumulate in the cytosol, where they form aggregates. The
caspase-3 reaction is inhibited by progranulin, which explains whymutations reducing the progranulin expression cause FTLD [110]. It is
not clear whether the disease is caused by a loss of nuclear function of
TDP43 or by a possible cytotoxic accumulation. However, siRNA
mediated knock down of TDP43 in HeLa cells followed by RNA
microarray analysis demonstrated a strong upregulation of cyclin-
dependent kinase 6 (cdk6). The human Cdk6 gene contains numerous
intronic TG repeats and interestingly a change in cdk6 expressionwas
not observed for the chicken gene that lacks these repeats. These data
strongly suggest that TDP43 represses cdk6 expression by sequester-
ing its RNA by binding to UG repeats. Loss of TDP43 expression leads to
abnormal cdk6 activity, resulting in pRB phosphorylation, genomic
instability and apoptosis, which could explain the cell death in FTLD
[111]. Mutations of the gene encoding TDP43 are found in families
with amyotrophic lateral sclerosis, as well as in sporadic cases,
indicating a direct link between TDP43 and amyotrophic lateral
sclerosis [112].
This example illustrates that splicing factors like TDP43 operate in
a regulatory network. A loss of their function can have drastic, but
indirect effects. HnRNPs typically perform several different functions,
which can obscure possible disease mechanisms. Finally, the interac-
tion between UG repeats of the cdk6 gene and TDP43 illustrate how an
hnRNP can be recruited to a new function during evolution.
2.1.8. Diseases associated with repeat elements
Short sequence repeats can be detected in numerous exons, where
they serve to increase the recognition by a certain splicing factor
[27,113], reviewed in [114]. A change in length of simple repeat
sequences can therefore change the splicing pattern of a gene. For
example, the endothelial NO synthase gene contains an intronic
polymorphic CA-repeat region and the number of repeats correlate
with the risk of coronary artery disease and hyperhomocysteinemie in a
sex-speciﬁc fashion [115]. SELEX experiments and functional studies
showed that CA repeats bind to hnRNP L and the action of hnRNP L
depends on the CA repeat length. Microarray studies showed that
intronic CA-rich repeats can inﬂuence alternative splicing decisions,
strongly suggesting that other intronic CA-repeat polymorphisms could
cause human disease [116]. Another disease-relevant repeat is the UG
repeat that can cause aberrant splicing of exon 9 of the CFTR gene,
leading to cystic ﬁbrosis [107]. This repeat binds to TDP43, which is
discussed below. Myotonic dystrophy (DM) is the most common form
of muscular dystrophy in adults. The disease is caused by extensions of
two repeats: a CUG repeat in the 3′ region of the DMPK gene leads to
DM1 and extension of a CCUG repeat in an intron of the ZNF9 gene leads
to DM2 [117]. The common CUG element binds to at least two groups of
RNA binding proteins, muscleblind-like1 and CUG binding protein.
Extension of the repeats leads a sequestration of muscleblind protein in
nuclear foci. This sequestration of muscleblind-like 1 protein reduces its
cellular concentration and changes alternative splicing events that
depend on this protein. Surprisingly, the extended CUG repeats lead to
an increase of CUG binding protein concentration. This increase is due
to a stabilization of CUG-binding protein. CUG RNA repeats induce via
an unknown mechanism protein kinase C, which phosphorylates the
CUG protein, leading to a more stable protein [118].
Alu elements are the largest group of repetitive elements in the
human genome. They represent about 10% of the total genome
sequence (reviewed in [63]). Alu elements contain potential splice
sites and can evolve into exons [61]. It has been estimated that up to
5% of human alternative exons could be derived from Alu sequences
[119]. It is therefore not surprising that mutations in existing Alu
elements can cause their abnormal inclusion in mRNA, which leads to
human diseases, such as the Alport syndrome [120], congenital
cataracts facial dysmorphism neuropathy syndrome [121], and
mucopolysaccharidosis type VII [122].
These examples illustrate how repeats can change the balance of
alternative splicing regulation, even when they are located in introns
or in seemingly unrelated mRNAs. The exonisation of Alu elements
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acquire new functions, and diseases caused by improper Alu-element
exonisations can be viewed as failed evolutionary experiments.
3. Numerous changes in alternative splicing are found in cancer
Numerous reports have shown that alternative splicing patterns are
changed in cancer (reviewed in [123]). The expression of alternative or
even tumour-speciﬁc splice variants signiﬁcantly affects many cellular
events critical for cancer biology such as cell proliferation, motility, and
drug response [124]. It is still unclear, however, to what extent
alternative splicing functionally contributes to the initiation and
progression of cancers. Most altered splicing patterns could be largely
symptomatic and attributed to a generalized lack of ﬁdelity of the
splicing apparatus in cancer cells. The existence of particular splice
variants in cancer could merely be a consequence of the malignant
phenotype without contributing to the cancer phenotype. Here we will
describe general changes of the splicingmachinery in cancer anddiscuss
speciﬁc examples illustrating the action on tumour suppressor genes.
3.1. Splicing regulatory factors and cancer
Changes in the concentration, localization, composition, or activity
of trans-acting regulatory factors, such as hnRNP and SR proteins, can
alter splice site selection. Several studies have demonstrated speciﬁc
alterations in the expression of splicing factors in cancer. The
increased phosphorylation and the elevated mRNA expression levels
of Tra2-beta1, YB-1 and classical SR proteins, including SC35 and ASF/
SF2, have been observed in human ovarian cancer and in mouse
models of breast cancer development [125–128].
One of the best characterized examples of splicing changes
observed in cancer tissues is CD44, a type 1 transmembrane
glycoprotein involved in cell–cell and cell–matrix interactions.
Alternative splicing of 10 of its 20 exons is found in association with
several biological processes, such as lymphocyte recruitment, epithe-
lial cell–matrix adhesion, and tumour metastasis. Due to its abundant
alternative splicing, it has been correlated with changes in splicing
factors, for example the concentration of ASF/SF2 or hnRNP A1 in
mouse lung tumours [129] and human colon carcinomas [130].
SF2/ASF is a prototypical splicing factor and has beenwidely used in
studying the connection between cancer and alternative splicing. SF2/
ASF controls alternative splicing of the oncogene Ron to modulate cell
motility, a general propertyofmetastatic cancer cells [131]. An increased
expression of SF2/ASF can transform NIH3T3 and Rat1 cells in vitro, and
NIH3T3 cells that express high levels of ASF/SF2 produce tumours in
vivo. This increase correlates with a change in splicing of genes involved
in the Ras-mitogen-activated protein kinase (MAPK) and the phopha-
tidylinositol-3-kinase (PI3K)-mammalian target of rapamycin (mTOR)
pathways, which are often deregulated in cancer. MNK2 and S6K1Table 3
Splicing mutations of tumour suppressor genes
Gene Mutation Ef
APC Donor splice site mutation in intron 4 Ex
APC G→A substitution at the splice acceptor site of intron 7 Cr
th
BRCA1 Non sense mutation in exon 18 AS
BRCA1 Intronic point mutation AA→AG (IVS5-12 G→A) Cr
Estrogen receptor AT→GT point mutation in intron 5 Cr
69
NF1 Double point mutation in exon 7 Di
NF2 Intronic CTAGC→CTAAC Co
cr
MLH1 Different codon 659 mutations Ex
tokinases involved in signal transduction are alternatively spliced in
response to elevated SF2/ASF concentration. A novel SF2/ASF-induced
isoform of S6K1 is sufﬁcient to cause a transformation phenotype.
Overexpression or knockdown of ASF/SF2 resulted in speciﬁc splicing
changes in a number of genes involved in these pathways. SF2/ASF
overexpression led to cellular transformation resulting in anchorage-
independent cell growth in soft-agar and tumour formation in nude
mice [132]. These data argue that SF2/ASF is a proto-oncogene [132]. It is
likely that other splicing factors have similar features.
3.2. Mutations of tumour suppressor genes affecting splice site selection
can cause cancer
Mutations in splicing regulatory elements that change splice site
selection provide a clear link between pre-mRNA processing and cancer
development. The mutations ultimately lead to the generation of non-
functional tumour suppressor genes, which predisposes to cancer. The
identiﬁcation and understanding of inherited mutations is important for
genetic counselling and for follow-up aimed at cancer prevention in
affected familymembers. A list ofwell-characterizedmutations is shown in
Table 3.
Themost frequent earlymolecular alteration in the initiation of colon
cancer involves mutations in the adenomatous polyposis coli (APC) gene,
whichoccurboth in rare familial cancer syndromesand in85%of sporadic
cancers. The majority of these mutations result in the truncation of the
APC gene product. Germline mutations in APC gene result in familial
adenomatous polyposis (FAP). Two mutations that disrupt splicing
regulatory elements have been found. The ﬁrst one affects a splicing
donor site in intron 4 resulting in skipping of exon 4 and leading to an
attenuated formof FAP [133]. This splicingderegulationwas found in liver
metastases, where the wild-type allele was deleted [134]. The second
mutation is a G to A substitution at the splice acceptor site of intron 7
creating a cryptic splice site and causing a single nucleotide deletion at
the beginning of exon 8 [134]. The behavior of these mutations can be
complicated by additional APC transcripts which are generated due to
alternative splicing of exons 3–4, 9, 10A/X, and 14 [135] [136,137]
The MMR MLH1 (MIM 120436) and MSH2 (MIM 609309) genes
responsible for hereditary nonpolyposis colorectal cancer (HNPCC or
Lynch syndrome; MIM 120435), are prone to mutations. Double exon
skipping in MLH1 gives rise to hereditary nonpolyposis colorectal
cancer [138,139]. Also in various hereditary nonpolyposis colorectal
cancer, different mutations in codon 659 result in skipping of exon 17
of MLH1 gene. This causes an internal deletion of 31 amino acids that
abrogates binding to the other mismatch repair protein PMS2 [140]. A
major difﬁculty in the diagnosis of the Lynch syndrome, like other
Mendelian diseases, is the interpretation of numerous variants of
unknown clinical and biological signiﬁcance. In most cases the
pathogenic role of the unclassiﬁed variants cannot be established
from clinical data and segregation analysis, because of the smallfect Reference
on 4 skipping → attenuated form of FAP [133]
yptic splice site creation causing a single nucleotide deletion a
e beginning of exon 8
[174]
F/SF2 ESE disruption→ exon 18 skipping [143]
yptic 3′ splice site creation→ production of a truncated protein [144]
yptic 5′ splice site creation in intron 5→ insertion of a
nucleotide cryptic exon into the reading frame
[175]
sruption of ASF/SF2 and SC35 ESE binding sites→ in frame deletion [147]
nsensus branch point adenosine creation → cryptic splice site
eation → additional exon 5a insertion
[148]
on 17 skipping → internal deletion of 31 aa that abrogates binding
the other mismatch repair protein PMS2
[140]
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MMR mutations and the possibility of additional undetected muta-
tions in the MMR genes. Recently, using an ex vivo functional splicing
assay based on a novel splicing reporter minigene to test 87 intronic or
exonic variants (20 and 67, respectively) corresponding to 85 alleles
found in MLH1 or MSH2 by the French HNPCC consortium, it was
possible to show that a high level of mutations alter splicing
regulatory elements [141]. However, the biological signiﬁcance of
the six variants is unknown.
Breast cancer gene 1 (BRCA1) is responsible for the majority of
hereditary breast and ovarian cancers [142]. Among sporadic cases of
breast cancer, expression of BRCA1 is reduced or undetectable in high-
grade ductal carcinomas, suggesting the involvement of this gene in the
etiology of breast cancer. Germline sequence variations in both splice
sites and regulatory elements of BRCA1 gene have been implicated in
susceptibility to cancer. For example, an inherited nonsensemutation in
exon 18 of the BRCA1 gene disrupts an Exonic Splicing Enhancer. This
enhancer binds to the SR protein SF2/ASF, and its mutation causes
inappropriate skipping of the constitutive exon 18 [143]. It has also been
shown that anAA toAGmutation creates a cryptic 3′ splice site that adds
11 nucleotides to BRCA1 mRNA, which encodes a truncated protein in a
breast cancer family [144]. In addition, multiple BRCA1 splice variants
are present in different tissues with different expression proﬁles [145].
The neuroﬁbromatosis 1 (NF1) gene that is linked to development of
neuroﬁbromas has one of the highest mutation rates described for any
human disorder, and a large proportion of NF1 mutations bear
consequences for the correct splicing of the RNA. A systematic study of
somatic NF1 mutations [146] demonstrated that most point mutations
resulted in splicing defects including exon skipping and the usage of
alternative 5′ and 3′ splice sites. Also, a double point mutation near the
middle of NF1 exon 7 has been found to cause a high level of in-frame
deletionof that exon. Thesemutationsdisrupt consensus binding sites for
the SR proteins SC35 and ASF/SF2 [147]. Somemutations like a CTAGC to
CTAAC in theNF1 gene in the central nervous system, create a consensus
branch point adenosine that activates a cryptic site in the intron leading
to an additional exon (exon 5a). Because some normal splicing remains,
this mutation is associated with a relatively mild phenotype [148].
These examples illustrate that numerous changes in splicing
patterns are characteristic for cancer development and progression.
It is currently not clear whether these changes are the cause or the
consequence of a malignant phenotype. Gain of function changes in
alternative splicing have been observed in several systems and well-
characterized examples are summarized in Table 4. These mutations,
and the mutations in the tumour suppressor genes that cause
missplicing and predispose cancer, are strongly suggesting that
aberrant processing of some pre-mRNAs is the cause of cancer and
could be a therapeutic target.Table 4
Gain of function of proteins promoting tumour development by alternative splicing
Gene Protein property/function Splice variant
Survivin Inhibitor of apoptosis Survivin 2B with pro-apoptotic propert
VEGF Role in angiogenesis Isoforms lacking exon 6
Cathepsin B Role in the development and
progression of cancers
Certain isoforms
FHIT Tumour suppressor Aberrant transcripts
Actinin 4 Actin-binding protein Variant Va, a mutually exclusive splice
where exon 8 is replaced by a new exo
the same size that exists in intron 8
AIB1 Hormone coactivator Isoform lacking exon 3
RON Tyrosine kinase receptor RonΔ165
RonΔ160
RonΔ1554. Treatment options for missplicing events
The examples discussed here clearly show that a misregulation of
alternative splicing plays a large role in numerous human diseases.
The identiﬁcation of molecules capable of correcting and or inhibiting
pathological splicing events is therefore an important issue for future
therapeutic approaches.4.1. Antisense strategies
The major challenge in treating splicing disorders is to speciﬁcally
target one splicing event in a certain pre-mRNA. Since there are several
thousand other pre-mRNAs in the cell, the selectivity of splice site
intervention is amajor problem.Oneway to address this problem is the
use of oligonucleotides that will speciﬁcally bind to one sequence.
Special chemistries were devised to prevent RNAseH-mediated
cleavage of the RNA and to lower toxicity (reviewed in [149,150]). A
majordrawback of the therapeutic use of oligonucleotides is their delivery
and uptake in the cells. This problem has been addressed by coupling of
oligonucleotides to arginine-rich cell penetrating peptides [151,152].
Antisense oligonucleotides have been tested for beta thalassemias
[153], Duchenne muscular dystrophy [154,155], cystic ﬁbrosis [156]
cyclophilin transcripts [157], Hutchinson Gilford Progeria Syndrome
(HGPS) [158] as well as block HIV replication [159] and alter tau pre-
mRNAs [160].
Antisense oligonucleotides can also be used to block splicing
enhancers or silencers, which can be found in introns or exons quite
far away from the splice sites [161]. Inhibition of splicing silencers
(ESSs or ISSs) is of particular interest since it provides away to activate
otherwise repressed exons. This was achieved for the α exon of
ﬁbroblast growth factor receptor-1 (FGFR1) transcripts [162] where an
antisense morpholino oligonucleotide that blocks silencer elements in
glioblastoma cells in culture promotes the inclusion of theα exon. The
antisense approach was further developed in ESSENSE (exon-speciﬁc
splicing enhancement by small chimeric effectors). ESSENSE uses
bifunctional reagents that contain a peptide effector domain and an
antisense-targeting domain. The effector domains of these protein-
nucleic acids were arginine-serine (RS) repeats that mimic the effect
of SR proteins [163]. A second incarnation of bifunctional oligomers
uses a 2′-Ome-modiﬁed binding domain and an effector domain,
which is composed of RNA that contains binding sites for known
splicing trans-acting factors[164],[165]. The recruited factors mediate
activation or silencing of the targeted exon. An example of this type of
bifunctional oligonucleotide acts as an ESE and promotes inclusion of
the SMN2 exon 7 ﬁbroblasts from SMA patients leading to partial
restoration of the SMN function [164].Isoform expression
in cancer
Cancer type Reference
ies Down regulated Breast carcinoma and late stage
or metastatic gastric cancer
[176,177]
Upregulated Non-small cell lung cancer [178]
Overexpressed Colon cancer [179]
Aberrant expression Gastric, cervical, thyroid and
testicular germ-cell tumours
[180–185]
variant
n of
Aberrant expression
of the splice isoform
Small cell lung cancer [186]
Aberrant expression Breast cancer [187]
Overexpressed Colorectal carcinoma [188,189]
23J. Tazi et al. / Biochimica et Biophysica Acta 1792 (2009) 14–264.2. Substances that change alternative splicing
The use of RNA-bindingmolecules as antibiotics, such as gentamicin,
chloramphenicol, and tetracycline illustrates that drugs can be targeted
against RNA and/or RNA binding proteins. High-throughput screens and
testing of substances in model systems have now identiﬁed more than
30 substances that change splice site selection. The substances fall into
several categories, including HDAC inhibitors, kinase and phosphatase
inhibitors, as well as cAMP antagonist and agonists. The currently
known substances are reviewed in [166] and updated on the web.
The usefulness of substances that change splice site selection is
evident from potential HIV therapies that could be combined with
other antiviral strategies. Using an in vitro splicing assay, a chemical
screenwas performed that identiﬁed an indole derivative (IDC16) that
interferes with exonic splicing enhancer activity of the SR protein
splicing factor SF2/ASF [167]. IDC16 suppresses the production of key
viral proteins and inhibits replication of macrophage- and Tcell-tropic
laboratory strains, clinical isolates, and strains with high-level
resistance to inhibitors of viral protease and reverse transcriptase.
Thus, human splicing factors represent novel and promising drug
targets for the development of antiretroviral therapies, particularly for
the inhibition of multidrug-resistant viruses.
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